Advanced Medical Isotope Corporation (OTC:ADMD)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E:


Latest News

Click here for more news and updates

Twitter • Industry News

Advanced Medical Isotope Corporation Appoints Dr. Ludwig E. Feinendegen to the Medical Advisory Board

KENNEWICK, WA / ACCESSWIRE / March 1, 2016 / Advanced Medical Isotope Corporation (AMIC) (OTC: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today announced that Dr. Ludwig E. Feinendegen, M.D. has been appointed to the Company's Medical Advisory Board.


Dr. Ludwig E. Feinendegen is a medical doctor known for his pioneering work and leadership in the fields of both diagnostic and therapeutic applications of radionuclides through various roles and research in nuclear medicine, internal medicine, cell biology and radiobiology. Dr. Feinendegen has numerous honors from national and international institutions and has authored over 700 publications in molecular nuclear medicine, cell biology and low-dose radiobiology.


Dr. Ludwig E. Feinendegen stated "AMIC's novel and intelligent approach to the therapeutic use of yttrium-90 to treat tumors is very exciting. I look forward to advising AMIC on the clinical use of their products and expansion into the European markets."


AMIC Founder, CEO and Chairman James C. Katzaroff stated "Dr. Feinendegen is an outstanding individual who has made remarkable contributions to the use of radionuclides for therapeutic and diagnostic purposes. We are pleased to welcome him, as an active and respected member of the international nuclear medicine community, to our Medical Advisory Board."


Dr. Feinendegen joins Dr. Darrell Fisher and Dr. Barry D. Pressman MD, FACR on the AMIC Medical Advisory Board. 


About Advanced Medical Isotope Corporation 

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website,

Safe Harbor Statement 


This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, AMIC's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.